ferric pyrophosphate citrate

General

Pronunciation:
fer-ik pye-roe-fos-fate sit-rate


Trade Name(s)

  • Triferic

Ther. Class.
antianemics

Pharm. Class.
iron supplements

Indications

Replacement of iron to maintain hemoglobin in patients with hemodialysis-dependent chronic kidney disease.

Action

Iron delivered into the circulation binds to transferrin for transport to erythroid precursor cells to be incorporated into hemoglobin.

Therapeutic Effect(s):

Maintenance of hemoglobin levels.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Minimal distribution to tissues.

Metabolism and Excretion: Unknown.

Half-life: 1.48 hr.

TIME/ACTION PROFILE (plasma concentrations)

ROUTEONSETPEAKDURATION
IVunknownunknownunknown

Contraindication/Precautions

Contraindicated in:

  • None.

Use Cautiously in:

  • OB:  Use during pregnancy only if the potential benefit justifies the potential risk to the fetus;
  • Lactation: Safety not established;
  • Rep:  Women of reproductive potential;
  • Pedi:  Safety and effectiveness not established.

Adverse Reactions/Side Effects

CNS: headache

CV: hypotension, peripheral edema

GU: urinary tract infection

MS: muscle spasms, pain

Resp: dyspnea

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS), fatigue, fever

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

None noted.

Route/Dosage

Intradialytic: (Adults)  Add one 5–mL ampule to each 2.5 gallons of bicarbonate concentrate  or  add one powder packet to each 25 gallons of the master bicarbonate mix.

Availability

Hemodialysis powder packet: 272 mg/pkt

Hemodialysis solution: 27.2 mg/5 mL

Assessment

  • Monitor for signs and symptoms of hypersensitivity reactions (shock, clinically significant hypotension, loss of consciousness, and/or collapse) during and after dialysis until clinically stable. Treat symptomatically.

Lab Test Considerations:

Measure iron levels on pre-dialysis blood samples; post-dialysis serum iron parameters may overestimate serum iron and transferrin saturation.

Potential Diagnoses

Implementation

  • Ampules appear slightly yellow-green in color. Add only to bicarbonate concentrate not to acid concentrate mixtures. Final concentration in final hemodialysate is 2 micromolar (110 mcg/L). Ampules can be added to bicarbonate mixture in a ratio of one 5–mg ampule/each 2.5 gallons or one 50–mg ampule/25 gallons. Powder can be added to bicarbonate mixture in a ratio of 1 packet/25 gallons. Use mixtures within 24 hr of mixing.

Patient/Family Teaching

  • Explain purpose of medication to patient.
  • Instruct patient to notify health care professional immediately if signs and symptoms of hypersensitivity reactions (rash, itching, dizziness, lightheadedness, swelling, breathing problems) occur.
  • Advise female patient to use effective contraception during and for at least 2 wks after completion of therapy. Advise patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

Maintenance of hemoglobin levels.

ferric pyrophosphate citrate is a sample topic from the Davis's Drug Guide.

To view other topics, please or .

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. .